Skip to content

HOME
ABOUT US
INVESTORS
PRESS ROOM
DISEASE FOCUS
INNOVATION
CLINICAL STUDIES
CONTACT

HOME
ABOUT US
INVESTORS
PRESS ROOM
DISEASE FOCUS
INNOVATION
CLINICAL STUDIES
CONTACT

Home
Scientific Presentations
Posiphen® Treatment is Able to Reduce APP Levels in Ta65Dn Mouse Model of Down Syndrome

Posiphen® Treatment is Able to Reduce APP Levels in Ta65Dn Mouse Model of Down Syndrome

Poster, 2008. ICAD, More>>>>>

Post navigation

QR Pharma to Present at the Alzheimer’s Association International Conference

Oral Posiphen® Treatment Lowers Aß42 in Mouse Brain

Search for:

Recent Posts

Targeting Alzheimer’s and Other Neurodegenerative Diseases via a Novel Mechanism of Action
Targeting Alzheimer’s with Novel Therapuetics
Healthcare Businesswomen’s Association: Women in Science – Winter 2011
Maria Maccecchini to Receive 2011 Iris Newmann Award – November 16, 2011
Maria Maccecchini, President and CEO of QR Pharma, Inc. to Serve on Panel with Nobel Laureate, Phillip Sharp at Chemical Heritage Foundation Event

QR Pharma, Inc. © All rights reserved

ABOUT US
PRIVACY POLICY
TERMS OF USE
SITE MAP
CONTACT

Scroll to Top